FDA’s Approach To Combination Pediatric Therapies: Monotherapy Comes First
This article was originally published in The Pink Sheet Daily
Executive Summary
Limited data limits the ability of companies to move to combination strategies, members of an advisory panel cautioned during a review of two checkpoint inhibitors.